Bionano Genomics (BNGO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BNGO Stock Forecast

Bionano Genomics stock forecast is as follows: an average price target of $59.33 (represents a 26978.96% upside from BNGO’s last price of $0.22) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

BNGO Price Target

The average price target for Bionano Genomics (BNGO) is $59.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $175.00 to $1.00. This represents a potential 26978.96% upside from BNGO's last price of $0.22.

BNGO Analyst Ratings

Buy

According to 5 Wall Street analysts, Bionano Genomics's rating consensus is 'Buy'. The analyst rating breakdown for BNGO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bionano Genomics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 28, 2024	Sung Ji Nam	Scotiabank	-	-	95.08%	356.41%
May 16, 2024	Mark Massaro	BTIG	-	-	73.91%	812.83%
May 25, 2023	Bionano Genomics's	EF Hutton	-	-	169.23%	79772.20%
Dec 12, 2022		BTIG	-	-	59.82%	159644.41%

Row per page

Go to

The latest Bionano Genomics stock forecast, released on Aug 28, 2024 by Sung Ji Nam from Scotiabank, set a price target of $1.00, which represents a 95.08% increase from the stock price at the time of the forecast ($0.51), and a 356.41% increase from BNGO last price ($0.22).

Bionano Genomics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$1.00	$1.50
Last Closing Price	$0.22	$0.22	$0.22
Upside/Downside	-100.00%	356.41%	584.62%

In the current month, the average price target of Bionano Genomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bionano Genomics's last price of $0.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 18, 2024	BTIG	Neutral	Neutral	Hold
Sep 10, 2024	BTIG	Buy	Neutral	Downgrade
Aug 28, 2024	Scotiabank	Sector Outperform	Sector Perform	Downgrade
May 16, 2024	BTIG	Buy	Buy	Hold
May 25, 2023	EF Hutton		Buy	Initialise
Jan 05, 2023	Scotiabank		Sector Outperform	Initialise
Jan 25, 2021	Odeon Capital Group LLC	Buy	Buy	Hold
Jan 16, 2021	Oppenheimer	Buy	Buy	Hold
Dec 30, 2020	Oppenheimer	Outperform	Outperform	Hold

Row per page

Go to

Bionano Genomics's last stock rating was published by BTIG on Nov 18, 2024. The company gave BNGO a "Neutral" rating, the same as its previous rate.

Bionano Genomics Financial Forecast

Bionano Genomics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$9.32M	$8.66M	$7.42M	$8.21M	$7.22M	$6.67M	$5.70M	$6.30M	$4.66M	$3.86M	$3.17M	$3.99M	$2.20M	$1.18M	$1.14M	$2.79M	$3.31M
Avg Forecast	$10.47M	$9.79M	$9.03M	$8.19M	$8.63M	$8.06M	$7.28M	$6.72M	$6.30M	$7.76M	$8.02M	$8.48M	$10.55M	$9.08M	$8.29M	$7.21M	$8.09M	$6.79M	$6.28M	$5.70M	$5.57M	$4.22M	$3.50M	$2.97M	$3.50M	$2.07M	$863.00K	$1.70M	$4.42M	$4.03M
High Forecast	$15.03M	$14.05M	$12.97M	$11.76M	$12.39M	$11.57M	$10.46M	$9.78M	$8.92M	$11.14M	$8.02M	$8.48M	$10.94M	$13.04M	$11.91M	$10.36M	$11.62M	$6.79M	$6.28M	$5.70M	$5.57M	$4.22M	$3.50M	$2.97M	$3.50M	$2.07M	$863.00K	$1.70M	$4.42M	$4.03M
Low Forecast	$7.61M	$7.11M	$6.57M	$5.95M	$6.27M	$5.86M	$5.30M	$4.79M	$4.67M	$5.64M	$8.02M	$8.48M	$9.94M	$6.60M	$6.03M	$5.25M	$5.89M	$6.79M	$6.28M	$5.70M	$5.57M	$4.22M	$3.50M	$2.97M	$3.50M	$2.07M	$863.00K	$1.70M	$4.42M	$4.03M
# Analysts	2	2	2	2	1	1	1	4	4	2	2	2	4	1	1	1	1	1	1	1	1	1	1	10	10	10	10	10	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.03%	1.04%	1.03%	1.01%	1.06%	1.06%	1.00%	1.13%	1.10%	1.10%	1.07%	1.14%	1.06%	1.37%	0.67%	0.63%	0.82%

Bionano Genomics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $10.55M, with a low forecast of $9.94M, and a high forecast of $10.94M. BNGO's average Quarter revenue forecast represents a 13.25% increase compared to the company's last Quarter revenue of $9.32M (Sep 23).

Bionano Genomics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	2	2	4	1	1	1	1	1	1	1	1	1	1	10	10	10	10	10	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-31.50M	$-39.24M	$-37.02M	$-36.80M	$-29.28M	$-29.69M	$-27.63M	$-17.10M	$-20.19M	$-18.05M	$-8.96M	$-10.56M	$-9.86M	$-7.21M	$-9.45M	$-6.71M	$-5.54M
Avg Forecast	$-10.47M	$-9.79M	$-9.03M	$-8.19M	$-8.63M	$-8.06M	$-7.28M	$-6.72M	$-6.30M	$-7.76M	$-8.02M	$-8.48M	$-10.55M	$-9.08M	$-8.29M	$-7.21M	$-8.09M	$-6.79M	$-6.28M	$-14.09M	$-5.57M	$-4.22M	$-3.50M	$-8.96M	$-3.50M	$-2.07M	$-7.21M	$-1.70M	$-4.42M	$-4.03M
High Forecast	$-7.61M	$-7.11M	$-6.57M	$-5.95M	$-6.27M	$-5.86M	$-5.30M	$-4.79M	$-4.67M	$-5.64M	$-8.02M	$-8.48M	$-9.94M	$-6.60M	$-6.03M	$-5.25M	$-5.89M	$-6.79M	$-6.28M	$-11.27M	$-5.57M	$-4.22M	$-3.50M	$-7.16M	$-3.50M	$-2.07M	$-5.77M	$-1.70M	$-4.42M	$-4.03M
Low Forecast	$-15.03M	$-14.05M	$-12.97M	$-11.76M	$-12.39M	$-11.57M	$-10.46M	$-9.78M	$-8.92M	$-11.14M	$-8.02M	$-8.48M	$-10.94M	$-13.04M	$-11.91M	$-10.36M	$-11.62M	$-6.79M	$-6.28M	$-16.91M	$-5.57M	$-4.22M	$-3.50M	$-10.75M	$-3.50M	$-2.07M	$-8.66M	$-1.70M	$-4.42M	$-4.03M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	3.47%	4.73%	5.13%	4.55%	4.31%	4.73%	1.96%	3.07%	4.78%	5.15%	1.00%	3.02%	4.77%	1.00%	5.55%	1.52%	1.37%

undefined analysts predict BNGO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bionano Genomics's previous annual EBITDA (undefined) of $NaN.

Bionano Genomics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	2	2	4	1	1	1	1	1	1	1	1	1	1	10	10	10	10	10	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-112.57M	$-38.91M	$-37.12M	$-38.68M	$-31.81M	$-32.16M	$-29.95M	$-34.38M	$-20.75M	$-18.79M	$-9.95M	$-11.73M	$-10.79M	$-8.07M	$-10.51M	$-7.90M	$-6.40M
Avg Forecast	$-4.53M	$-4.25M	$-5.89M	$-6.90M	$-5.59M	$-5.71M	$-7.15M	$-8.16M	$-11.58M	$-16.96M	$-35.66M	$-55.31M	$-74.77M	$-83.26M	$-89.52M	$-89.76M	$-96.52M	$-76.59M	$-60.82M	$-14.12M	$-44.25M	$-38.91M	$-30.41M	$-9.95M	$-35.48M	$-35.48M	$-8.07M	$-145.30M	$-121.65M	$-405.50M
High Forecast	$-2.92M	$-2.74M	$-3.80M	$-4.45M	$-3.60M	$-3.68M	$-4.61M	$-5.27M	$-7.47M	$-10.94M	$-23.01M	$-35.68M	$-64.45M	$-53.72M	$-57.75M	$-57.91M	$-62.27M	$-76.59M	$-60.82M	$-11.30M	$-44.25M	$-38.91M	$-30.41M	$-7.96M	$-35.48M	$-35.48M	$-6.46M	$-145.30M	$-121.65M	$-405.50M
Low Forecast	$-7.09M	$-6.66M	$-9.22M	$-10.81M	$-8.75M	$-8.94M	$-11.19M	$-12.79M	$-18.14M	$-26.57M	$-55.86M	$-86.64M	$-86.80M	$-130.42M	$-140.22M	$-140.60M	$-151.19M	$-76.59M	$-60.82M	$-16.94M	$-44.25M	$-38.91M	$-30.41M	$-11.94M	$-35.48M	$-35.48M	$-9.69M	$-145.30M	$-121.65M	$-405.50M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.35%	0.43%	0.41%	0.40%	0.42%	0.53%	2.12%	0.78%	0.53%	0.62%	1.00%	0.33%	0.30%	1.00%	0.07%	0.06%	0.02%

Bionano Genomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNGO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Bionano Genomics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	2	2	4	1	1	1	1	1	1	1	1	1	1	10	10	10	10	10	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$24.90M	$26.94M	$25.98M	$25.32M	$21.22M	$21.78M	$20.28M	$19.81M	$15.33M	$13.83M	$9.53M	$9.43M	$8.66M	$5.61M	$7.37M	$5.86M	$4.45M
Avg Forecast	$30.81M	$28.79M	$26.58M	$24.09M	$25.39M	$23.71M	$21.43M	$19.79M	$18.53M	$22.82M	$23.60M	$24.96M	$31.05M	$26.72M	$24.40M	$21.23M	$23.82M	$19.99M	$18.49M	$16.78M	$16.40M	$12.42M	$10.31M	$8.74M	$10.29M	$6.08M	$2.54M	$5.01M	$13.01M	$11.86M
High Forecast	$44.23M	$41.34M	$38.16M	$34.59M	$36.45M	$34.03M	$30.77M	$28.78M	$26.25M	$32.77M	$23.60M	$24.96M	$32.18M	$38.36M	$35.03M	$30.48M	$34.20M	$19.99M	$18.49M	$16.78M	$16.40M	$12.42M	$10.31M	$8.74M	$10.29M	$6.08M	$2.54M	$5.01M	$13.01M	$11.86M
Low Forecast	$22.40M	$20.93M	$19.33M	$17.52M	$18.46M	$17.23M	$15.58M	$14.09M	$13.75M	$16.59M	$23.59M	$24.96M	$29.25M	$19.43M	$17.74M	$15.43M	$17.32M	$19.99M	$18.49M	$16.78M	$16.40M	$12.42M	$10.31M	$8.74M	$10.29M	$6.08M	$2.54M	$5.01M	$13.01M	$11.86M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.93%	1.10%	1.22%	1.06%	1.06%	1.18%	1.21%	1.21%	1.23%	1.34%	1.09%	0.92%	1.42%	2.21%	1.47%	0.45%	0.38%

Bionano Genomics's average Quarter SG&A projection for Dec 23 is $31.05M, based on 4 Wall Street analysts, with a range of $29.25M to $32.18M. The forecast indicates a 24.72% rise compared to BNGO last annual SG&A of $24.90M (Sep 23).

Bionano Genomics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	2	2	4	1	1	1	1	1	1	1	1	1	1	10	10	10	10	10	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.22	$-1.24	$-0.12	$-0.13	$-0.11	$-0.11	$-0.11	$-0.12	$-0.07	$-0.07	$-0.04	$-0.06	$-0.08	$-0.09	$-0.30	$-0.23	$-0.59
Avg Forecast	$-0.05	$-0.05	$-0.07	$-0.08	$-0.07	$-0.07	$-0.08	$-0.10	$-0.13	$-0.20	$-0.42	$-0.64	$-0.87	$-0.97	$-1.04	$-1.05	$-1.12	$-1.13	$-0.90	$-0.75	$-0.65	$-0.58	$-0.45	$-0.45	$-0.53	$-0.53	$-0.87	$-2.15	$-1.80	$-6.00
High Forecast	$-0.03	$-0.03	$-0.04	$-0.05	$-0.04	$-0.04	$-0.05	$-0.06	$-0.09	$-0.13	$-0.27	$-0.42	$-0.75	$-0.63	$-0.67	$-0.67	$-0.73	$-1.13	$-0.90	$-0.75	$-0.65	$-0.58	$-0.45	$-0.45	$-0.53	$-0.53	$-0.87	$-2.15	$-1.80	$-6.00
Low Forecast	$-0.08	$-0.08	$-0.11	$-0.13	$-0.10	$-0.10	$-0.13	$-0.15	$-0.21	$-0.31	$-0.65	$-1.01	$-1.01	$-1.52	$-1.63	$-1.64	$-1.76	$-1.13	$-0.90	$-0.75	$-0.65	$-0.58	$-0.45	$-0.45	$-0.53	$-0.53	$-0.87	$-2.15	$-1.80	$-6.00
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	3.32%	1.19%	0.11%	0.12%	0.10%	0.12%	0.15%	0.18%	0.12%	0.16%	0.09%	0.12%	0.15%	0.10%	0.14%	0.13%	0.10%

According to undefined Wall Street analysts, Bionano Genomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNGO previous annual EPS of $NaN (undefined).

Bionano Genomics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BNGO	Bionano Genomics	-	-	26868.18%	Buy
STAA	STAAR Surgical Company	-	-	104.96%	Buy
BDX	Becton, Dickinson and Company	-	-	25.65%	Buy
NVST	Envista	-	-	8.04%	Hold
WST	West Pharmaceutical Services	-	-	-7.23%	Buy
RMD	ResMed	-	-	-10.05%	Hold
ISRG	Intuitive Surgical	-	-	-18.43%	Buy

BNGO Forecast FAQ

Is Bionano Genomics a good buy?

Yes, according to 5 Wall Street analysts, Bionano Genomics (BNGO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of BNGO's total ratings.

What is BNGO's price target?

Bionano Genomics (BNGO) average price target is $59.33 with a range of $1 to $175, implying a 26978.96% from its last price of $0.219. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bionano Genomics stock go up soon?

According to Wall Street analysts' prediction for BNGO stock, the company can go up by 26978.96% (from the last price of $0.219 to the average price target of $59.33), up by 79772.20% based on the highest stock price target, and up by 356.41% based on the lowest stock price target.

Can Bionano Genomics stock reach $0?

BNGO's average twelve months analyst stock price target of $59.33 supports the claim that Bionano Genomics can reach $0 in the near future.

What are Bionano Genomics's analysts' financial forecasts?

Bionano Genomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $30.69M (high $44.19M, low $22.21M), average EBITDA is $-30.694M (high $-22.214M, low $-44.193M), average net income is $-26.605M (high $-17.164M, low $-41.674M), average SG&A $90.32M (high $130.04M, low $65.36M), and average EPS is $-0.31 (high $-0.2, low $-0.485). BNGO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $37.48M (high $53.81M, low $27.25M), average EBITDA is $-37.479M (high $-27.248M, low $-53.806M), average net income is $-21.566M (high $-13.913M, low $-33.781M), average SG&A $110.28M (high $158.32M, low $80.18M), and average EPS is $-0.251 (high $-0.162, low $-0.393).

Did the BNGO's actual financial results beat the analysts' financial forecasts?

Based on Bionano Genomics's last annual report (Dec 2023), the company's revenue was $36.12M, beating the average analysts forecast of $35.14M by 2.78%. Apple's EBITDA was $-215M, beating the average prediction of $-35.141M by 512.53%. The company's net income was $-232M, missing the average estimation of $-337M by -31.08%. Apple's SG&A was $93.5M, missing the average forecast of $103.4M by -9.58%. Lastly, the company's EPS was $-6.81, beating the average prediction of $-3.928 by 73.36%. In terms of the last quarterly report (Sep 2023), Bionano Genomics's revenue was $9.32M, beating the average analysts' forecast of $9.08M by 2.62%. The company's EBITDA was $-31.5M, beating the average prediction of $-9.08M by 246.90%. Bionano Genomics's net income was $-113M, beating the average estimation of $-83.265M by 35.19%. The company's SG&A was $24.9M, missing the average forecast of $26.72M by -6.82%. Lastly, the company's EPS was $-3.22, beating the average prediction of $-0.97 by 232.08%